Ismail Ammar, Boateng William K B, Alnakeb Amira, Botros Youssef, Cruz Allan L
Jersey City Medical Center, Rutgers New Jersey Medical School, Jersey City, New Jersey, USA.
Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Case Rep Gastrointest Med. 2025 Jul 22;2025:8864636. doi: 10.1155/crgm/8864636. eCollection 2025.
Metastasis to the duodenum from colorectal cancer is exceptionally rare and presents significant diagnostic and therapeutic challenges. We describe a 68-year-old female with right colon adenocarcinoma, who developed a duodenal metastasis despite treatment with FOLFOX chemotherapy. Transition to FOLFIRI yielded limited success, emphasizing the need for innovative approaches. Genetic analysis revealed a KRAS G12D mutation, for which targeted therapies are not yet approved. Immunohistochemistry confirmed the gastrointestinal origin of the duodenal mass. Literature indicates that surgical resection can offer curative potential in select cases, although it was not viable here. Emerging KRAS-targeted agents, such as MRTX1133, represent promising options for addressing this mutation. This case underscores the challenges of managing rare metastatic patterns, the potential of personalized therapies, and the necessity for further research into innovative treatments for advanced colorectal cancer. It highlights the importance of developing targeted strategies to improve outcomes for patients with such complex metastatic diseases.
结直肠癌转移至十二指肠极为罕见,且带来了重大的诊断和治疗挑战。我们描述了一名68岁患有右半结肠癌的女性,尽管接受了FOLFOX化疗,但仍发生了十二指肠转移。改用FOLFIRI化疗效果有限,这凸显了创新治疗方法的必要性。基因分析显示存在KRAS G12D突变,针对该突变的靶向治疗尚未获批。免疫组化证实十二指肠肿物起源于胃肠道。文献表明,在某些病例中手术切除可能具有治愈潜力,尽管在此例中不可行。新兴的KRAS靶向药物,如MRTX1133,是应对这种突变的有前景的选择。该病例强调了处理罕见转移模式的挑战、个性化治疗的潜力以及对晚期结直肠癌创新治疗进行进一步研究的必要性。它突出了制定靶向策略以改善此类复杂转移性疾病患者治疗效果的重要性。